Chemistry & Industry

Issue 9 2023

Show me
All pages
All themes
All issues
search by





Neil Eisberg

Neil Eisberg


US pharma flounders

It used to be simple – or at least relatively straightforward. Big Pharma relied on ‘blockbuster’ drugs to provide profits and financial support for R&D. Then biotech became the ‘next big thing’ with small start-up companies, often spin-outs from university research and funded by venture capitalists. Big Pharma took advantage of this, in many cases, first through collaboration and then acquisition to add products to their portfolios and expertise.

Read the full article

Business Digest

All the latest mergers and acquisitions, major projects and investments throughout the industry.

Read the latest business digest
Business digest icon

Movers & Shakers

Keep up-to-date with who works where with our exclusive review of personnel across the chemistry-using industries.

Read the latest Movers & Shakers
Movers & Shakers

Supply Line

Get your product noticed. Let C&I give it the profile it deserves. Contact Genevieve Kanowski on +49 6201606 638 or by email to get into the next Supply Line.

Previous Issues

Want more C&I?

C&I app - Apple iOS

Download for Apple iOS

C&I app - Android

Download for Android